As of 2025-06-02, the Intrinsic Value of Bridge Biotherapeutics Inc (288330.KQ) is (12,467.47) KRW. This 288330.KQ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 731.00 KRW, the upside of Bridge Biotherapeutics Inc is -1,805.50%.
The range of the Intrinsic Value is (109,428.46) - (6,833.17) KRW
Based on its market price of 731.00 KRW and our intrinsic valuation, Bridge Biotherapeutics Inc (288330.KQ) is overvalued by 1,805.50%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (109,428.46) - (6,833.17) | (12,467.47) | -1805.5% |
| DCF (Growth 10y) | (6,807.35) - (98,756.79) | (11,892.58) | -1726.9% |
| DCF (EBITDA 5y) | (4,624.12) - (8,500.22) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (5,037.06) - (8,970.19) | (1,234.50) | -123450.0% |
| Fair Value | -1,892.68 - -1,892.68 | -1,892.68 | -358.92% |
| P/E | (3,868.64) - (6,866.65) | (5,753.75) | -887.1% |
| EV/EBITDA | (4,482.86) - (7,370.38) | (5,973.36) | -917.1% |
| EPV | (6,522.90) - (9,414.68) | (7,968.79) | -1190.1% |
| DDM - Stable | (6,199.45) - (151,916.77) | (79,058.06) | -10915.1% |
| DDM - Multi | (5,507.08) - (106,933.72) | (10,562.60) | -1545.0% |
| Market Cap (mil) | 38,150.89 |
| Beta | -1.23 |
| Outstanding shares (mil) | 52.19 |
| Enterprise Value (mil) | 35,039.39 |
| Market risk premium | 5.82% |
| Cost of Equity | 6.16% |
| Cost of Debt | 8.52% |
| WACC | 6.19% |